Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease

Gene

Volumn 504, Issue 2, 2012, Pages 292-295

  Narajczyk, Magdalena ^a   Tylki Szymańska, Anna ^b   Wegrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Gene expression targeted isoflavone therapy; Hair morphology; Mucopolysaccharidosis; Sanfilippo disease; Scanning electron microscopy

Indexed keywords

GENISTEIN; ISOFLAVONE; SOYFEM; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; GENE EXPRESSION TARGETED ISOFLAVONE THERAPY; HAIR ANALYSIS; HAIR MORPHOLOGY; HUMAN; MOLECULARLY TARGETED THERAPY; MORPHOLOGY; PRIORITY JOURNAL; SANFILIPPO SYNDROME; SCANNING ELECTRON MICROSCOPY; TREATMENT DURATION;

BIOLOGICAL MARKERS; GENE EXPRESSION; HAIR; HUMANS; ISOFLAVONES; MUCOPOLYSACCHARIDOSIS III;

EID: 84862753666     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.05.006     Document Type: Article

References (21)

1. Barranger J.A., Cabrera-Salazar M. Lysosomal Storage Disorders 2007, Springer, Berlin-Heidelberg.
2. de Ruijter J., Valstar M.J., Wijburg F.A. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Curr. Pharm. Biotechnol. 2011, 12:923-930.
3. de Ruijter J., Valstar M.J., Narajczyk M., Wegrzyn G., Kulik W., Ijlst L., Wagemans T., van der Wal W.M., Wijburg F.A. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann. Neurol. 2012, 71:110-120.
4. Delgadillo V., del Mar O'Callaghan M., Artuch R., Montero R., Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J. Inherit. Metab. Dis. 2011, 34:1039-1044.
5. Jakóbkiewicz-Banecka J., Piotrowska E., Narajczyk M., Barańska S., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J. Biomed. Sci. 2009, 16:26.
6. Jakóbkiewicz-Banecka J., et al. Substrate reduction therapies for mucopolysaccharidoses. Curr. Pharm. Biotechnol. 2011, 12(11):1860-1865.
7. Kloska A., et al. Changes in hair morphologyof mucopolysaccharidosis I patients treated with recombinant human α-L-iduronidase (laronidase, Aldurazyme). Am. J. Med. Genet. A 2005, 139:199-203.
8. Kloska A., Jakóbkiewicz-Banecka J., Narajczyk M., Banecka-Majkutewicz Z., Wegrzyn G. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab. Brain Dis. 2011, 26:1-8.
9. Malinova V., Wegrzyn G., Narajczyk M. The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy (GET IT) for Sanfilippo disease patients. J. Inherit. Metab. Dis. Rep. 2011, 10.1007/8904_2011_87.
10. Malinowska M., et al. Abnormalities in the hair morphology of patients of same but not all types of mucopolysaccharidoses. Eur. J. Pediatr. 2008, 167:203-209.
11. Malinowska M., et al. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet. Metab. 2009, 98:235-242.
12. Malinowska M., et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010, 5:e14192.
13. Neufeld E.F., Muenzer J. Mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill Co., New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
14. Piotrowska E., et al. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 2006, 14:846-852.
15. Piotrowska E., et al. The use of genistein-rich isoflavone extract in substrate reduction therapy for Sanfilippo disease: open-label, pilot study in 10 pediatric patients. Curr. Ther. Res. Clin. Exp. 2008, 69:166-179.
16. Piotrowska E., et al. Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med. Sci. Monit. 2011, 17:CR196-202.
17. Swarts K. Genetic Disorders 2009, Greenhaven Press, Farmington Hills, MI.
18. Valstar M.J., Ruijter G.J., van Diggelen O.P., Poorthuis B.J., Wijburg F.A. Sanfilippo syndrome: a mini-review. J. Inherit. Metab. Dis. 2008, 31:240-252.
19. Valstar M.J., et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann. Neurol. 2010, 68:876-887.
20. Valstar M.J., Marchal J.P., Grootenhuis M., Colland V., Wijburg F.A. Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet J. Rare Dis. 2011, 6:43.
21. Wegrzyn G., et al. Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem. Soc. Trans. 2010, 38:695-701.